New RH5-based malaria prophylaxis with stronger infection inhibition
RH5 is the leading target for blood-stage malaria vaccines. Now, human mAbs have been isolated and studied for the first time, providing strategies for biologics development, vaccine design and seasonal prophylactic use.
Applications: Malaria vaccine design, biologics, antimalarial drug development
| Features | Benefits |
|---|---|
| Identification of neutralising (blue) and non-neutralising (green) mAbs that together bind RH5 to synergistically inhibit merozoite (MZ) invasion of red blood cells (RBC) | Facilitate structure-guided prophylaxis and biologics development to maximize antibody efficacy against blood-stage malaria |
| Potentiation of neutralising antibodies by non-neutralising antibodies | Antimalarial antibody combinations that neutralise merozoites with a higher potency than ever before |
| Uses human antibodies | Better for human drug development than animal-derived antibodies |
| Multiple, distinct neutralising binding sites identified | Increased targeting to enhance neutralisation |
Patented and Available For
- Co-development
- Consulting
- Licensing